These two divergent models of liver dysfunction were selected to explore the broad potential application and associated mechanisms of GLP-1 based therapies on various hallmark characteristics of NAFLD, as well as on hepatic regeneration following PH in differing metabolic contexts. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.